Martin Špaček, Lukáš Smolej, Martin Šimkovič, Lucie Nekvindová, Zlatuše Křístková, Yvona Brychtová, Anna Panovská, Stanislava Mašlejová, Lucie Bezděková, Dominika Écsiová, Pavel Vodárek, Jana Zuchnická, Jana Mihályová, Renata Urbanová, Peter Turcsányi, Daniel Lysák, Jan Novák, Martin Brejcha, Tereza Líkařová, Prokop Vodička, Jana Baranová, Marek Trněný, Michael Doubek
Idelalisib (idela), a phosphatidylinositol 3-kinase inhibitor, and ibrutinib, a Bruton tyrosine kinase inhibitor, were the first oral targeted agents approved for relapsed/refractory (R/R) chronic lymphocytic leukaemia (CLL). However, no randomised trials of idelalisib plus rituximab (R-idela) versus ibrutinib have been conducted. Therefore, we performed a real-world retrospective analysis of patients with R/R CLL treated with R-idela (n = 171) or ibrutinib (n = 244). The median age was 70 versus 69 years, with a median of two previous lines...
March 27, 2023: British Journal of Haematology